These 10 shares done the best performance in the last edition in share market
BSE mid-cap index slips 9% in 2018 Due to the domestic macro-economic concerns with high valuation and global investors, the appellants were skeptical in the Sankhya 2074 ending on Tuesday.
In the year 2018, there was a slight increase in the stock market. In the last one year, the Sensex rose 8% and the Nifty was up 3.8%. This is the worst performance of the market since the end of November 2015. That year, the benchmark indices dropped 2.4-3.7%. BSE mid-cap index slips 9% in 2018 Due to the domestic macro-economic concerns with high valuation and global investors, the appellants were skeptical in the Sankhya 2018 ending on Tuesday. However, in the last one year many stocks have performed well. The Economic Times is investigating such 10 stocks. We are also telling how their performance could be in the coming time.
1. HEG
Share price: ₹ 4,124.4
Changes in Samvat 2074: 226.2%
Forward P / E: 5.20
Consensual rating: 5 by / 0 hold / 0 cell
Consensus Target Price: ₹ 6,198
The company has gained rapidly the cost of graphite electrodes. Market analysts are saying that if an investor wants to bet on this sector, then this is the best stock for them. Bank of America Merrill Lynch wrote in a recent note that the graphite electrode has increased the company's profitability by five times in the last one year. It is trading at 3.8 times the estimated EPS of FY 2020, which is less valuation than China and Japan's graphite electrodes companies. He started with HEG coverage by rating. The bank has set a target price of Rs 6,700 for this, which is 62% more than the existing level.
2. Graphite India
Share price: ₹ 981.05
Changes in Samvat 2074: 115.8%
Forward P / E: 5.75
Consensus rating: 6 bye / 1 hold / 1 cell
Consensus Target Price: ₹ 1,388
Graphite India has also benefited from the increase in the cost of graphite electrodes. This too has been in the eyes of the investors in the past. Like HEG, shares of Graphite India are also getting lesser valuation than companies in this segment in China and Japan. Bank of America Merrill Lynch started the coverage of this stock with the target price of 1,550 rupees. Brokerage House said, "With the sharp increase in profits, the company's annual cash flow may increase by 23-35 billion rupees over the next three years. This allows the company to increase dividend. He can use it in a related industry such as graphene, which will further increase its growth. '
3. L & T Technology Services
Share price: ₹ 1,661.65
Changes in the Samvat 2074: 109.8%
Forward P / E: 25
Consensus rating: 12 by / 3 hold / 1 cell
Consensus Target Price: ₹ 1,792.21
The performance of engineering services company L & T Technology can be good due to the speed in engineering design services in the near future. Brokerage firm Prabhudas Liladhar said, "Management has increased revenue guidance to 21% for the financial year 2019 to 21%. Earlier, he gave guidance of 16%. "Brokerage House says that this guidance is conservative and the revenue growth of the company can be higher than that. Prabhudas Leeladhar gave the Accumulat rating to the stock and fixed the target price of Rs. 1,780. Edelweiss Securities has also raised its target price from Rs 1,725 to Rs 1,820. He said that the company has performed brilliantly in all the areas and its growth will remain intensified.
4. L & T Infotech
Share price: ₹ 1,691.85
Changes in Samvat 2074: 109.1%
Forward P / E: 19.85
Consensual rating: 20 by / 3 hold / 0 cell
Consensus Target Price: 1,997.57
L & T Infotech has consistently performed outperforms due to consistent performance in terms of earnings and margins. Antique stock broking has given it a buy rating of $ 2,140 with the target price. It is trading at 18.6 times the estimated EPS of FY2019, which is an attractive valuation considering the growth in the business. Brokerage House wrote in a recent note, "L & T Infotech Midcap remains our most preferred company in IT. The company's earnings and margins are continuously rising. So we like this stock. "Kotak Institutional Equities recently said that considering the rapid growth of L & T Infotech, it should get higher valuation. The company has a large number of clients He has good potential in the digital segment. The brokerage house said that its growth will continue to grow fast in the coming days.
5. Division Labs
Share price: ₹ 1,478.55
Changes in Samvat 2074: 68.45%
Forward P / E: 32.12
Consensual rating: 14 bye / 1 hold / 1 cell
Consensus Target Price: ₹ 1,555.50
Division Labs is quite strong in the Contract Research and Manufacturing Services Segment. This gives the stock a touch. However, HDFC Securities had recently stated in a report that it is trading at 30 times the estimated EPS of FY2019, which is 20% more than its historical valuation. The brokerage house had recently downgraded the stock and had categorized its rating. HDFC Securities has set a target price of Rs 1,345 for division labs. Motilal Oswal also kept a neutral rating on the stock in a note in October. He has set a target of Rs 1,390 for this.
6. Biocon
Share price: ₹ 629.3
Changes in Samvat 2074: 64.73%
Forward P / E: 57.07
Consensus rating: 12 by / 2 hold / 6 cells
Consensus Target Price: ₹ 650.90
In the past some time, the interest of investors has increased in the company due to the increase in the biologics segment. Motilal Oswal says that later biological business can be strong performance. At the same time, the performance of the company's approved biosimillers in regulators and emerging markets will also be excellent. However, analysts are apprehensive of high valuation of Biocon. Motilal Oswal has given it a neutral rating. He says that the share price of Biocon is not very fast. At the same time, Centrum Broking wrote in a recent report that recently the shares of Biocon have gained a lot, making it expensive. The brokerage firm advised to switch from Aurobindo Pharma or Pfizer. He gave biocon cell rating with target price of 480 rupees.
7. TCS
Share price: ₹ 1,931.95
Changes in Samvat 2074: 49.4%
Forward P / E: 22.90
Consensual rating: 24 bye / 17 hold / 9 cells
Consensus Target Price: ₹ 2,134.89
Due to the weakness in the rupee and the defensive sector, including IT, TCS has done outperform due to the financial condition. Sharekhan, a proprietary brokerage firm owned by BNP Paribas, has given a buy rating to TCS with target price of 2,400 rupees. He said, 'We believe that compared to other big IT companies, TCS's shares will continue to meet higher valuations. The company is strong enough in the digital segment. Its organic growth is the best in big IT companies. Its digital business is also getting better.
8. Infosys
Share price: ₹ 666.80
Changes in Samvat 2074: 45.4%
Forward P / E: 22.9
Consensual rating: 24 bye / 17 hold / 9 cells
Consensus Target Price: 790.14
In addition to the Future Sentiment related to BFSI Vertical, there is a positive segmentation about the stock with faster growth. Brokerage firm Prabhudas Liladhar has written in a note, "Infosys is trading at 22% less valuation than TCS. We believe that the valuation of Infosys is attractive because its business is also improving. We believe that its valuation gap may be lower than TCS. "Brokerage House has given a buy rating of Rs 790 with Target Price of Infosys at Rs 790.
9. United Breweries
Share price: ₹ 1,252.25
Changes in Samvat 2074: 48.65%
Forward P / E: 64.97
Consensual rating: 5 bye / 1 hold / 3 cell
Consensus Target Price: ₹ 1,317.75
Growth in beer volume and profitability after the highway ban has improved significantly in United Breweries growth and profitability. Brokerage house MK Global said, 'We expect the company to profit margins.' United Breweries is trying to reduce costs. Recovery is occurring in its high margin market and the volume of volume increases, operating leverage is also increasing. There is also a steady increase in its market share. We believe that United Breweries will benefit greatly due to low competition in the beer market. "MK Global has estimated 28 percent CAGR increase in the company profits between 2019 and 2021. He says that in the meanwhile, the company's Return on Capital Employee will also improve. In this sense, the price at which it is trading is appealing.
10. GlaxoSmithKline Consumer Healthcare
Share price: ₹ 7,102.45
Changes in Samvat 2074: 43.9%
Forward P / E: 34.24
Consensual rating: 18 bye / 6 hold / 1 cell
Consensus target price: ₹ 7,914.06
Analysts say that GSK Consumer Performance has improved significantly. Management is focusing on new variants and channels, whose company is benefiting. Edelweiss Securities has raised the target price of the stock from Rs 6,604 to Rs 7,297, but has maintained its hold rating on it. Prabhudas Leeladhar also gave it a hold rating.
BSE mid-cap index slips 9% in 2018 Due to the domestic macro-economic concerns with high valuation and global investors, the appellants were skeptical in the Sankhya 2074 ending on Tuesday.
In the year 2018, there was a slight increase in the stock market. In the last one year, the Sensex rose 8% and the Nifty was up 3.8%. This is the worst performance of the market since the end of November 2015. That year, the benchmark indices dropped 2.4-3.7%. BSE mid-cap index slips 9% in 2018 Due to the domestic macro-economic concerns with high valuation and global investors, the appellants were skeptical in the Sankhya 2018 ending on Tuesday. However, in the last one year many stocks have performed well. The Economic Times is investigating such 10 stocks. We are also telling how their performance could be in the coming time.
1. HEG
Share price: ₹ 4,124.4
Changes in Samvat 2074: 226.2%
Forward P / E: 5.20
Consensual rating: 5 by / 0 hold / 0 cell
Consensus Target Price: ₹ 6,198
The company has gained rapidly the cost of graphite electrodes. Market analysts are saying that if an investor wants to bet on this sector, then this is the best stock for them. Bank of America Merrill Lynch wrote in a recent note that the graphite electrode has increased the company's profitability by five times in the last one year. It is trading at 3.8 times the estimated EPS of FY 2020, which is less valuation than China and Japan's graphite electrodes companies. He started with HEG coverage by rating. The bank has set a target price of Rs 6,700 for this, which is 62% more than the existing level.
2. Graphite India
Share price: ₹ 981.05
Changes in Samvat 2074: 115.8%
Forward P / E: 5.75
Consensus rating: 6 bye / 1 hold / 1 cell
Consensus Target Price: ₹ 1,388
Graphite India has also benefited from the increase in the cost of graphite electrodes. This too has been in the eyes of the investors in the past. Like HEG, shares of Graphite India are also getting lesser valuation than companies in this segment in China and Japan. Bank of America Merrill Lynch started the coverage of this stock with the target price of 1,550 rupees. Brokerage House said, "With the sharp increase in profits, the company's annual cash flow may increase by 23-35 billion rupees over the next three years. This allows the company to increase dividend. He can use it in a related industry such as graphene, which will further increase its growth. '
3. L & T Technology Services
Share price: ₹ 1,661.65
Changes in the Samvat 2074: 109.8%
Forward P / E: 25
Consensus rating: 12 by / 3 hold / 1 cell
Consensus Target Price: ₹ 1,792.21
The performance of engineering services company L & T Technology can be good due to the speed in engineering design services in the near future. Brokerage firm Prabhudas Liladhar said, "Management has increased revenue guidance to 21% for the financial year 2019 to 21%. Earlier, he gave guidance of 16%. "Brokerage House says that this guidance is conservative and the revenue growth of the company can be higher than that. Prabhudas Leeladhar gave the Accumulat rating to the stock and fixed the target price of Rs. 1,780. Edelweiss Securities has also raised its target price from Rs 1,725 to Rs 1,820. He said that the company has performed brilliantly in all the areas and its growth will remain intensified.
4. L & T Infotech
Share price: ₹ 1,691.85
Changes in Samvat 2074: 109.1%
Forward P / E: 19.85
Consensual rating: 20 by / 3 hold / 0 cell
Consensus Target Price: 1,997.57
L & T Infotech has consistently performed outperforms due to consistent performance in terms of earnings and margins. Antique stock broking has given it a buy rating of $ 2,140 with the target price. It is trading at 18.6 times the estimated EPS of FY2019, which is an attractive valuation considering the growth in the business. Brokerage House wrote in a recent note, "L & T Infotech Midcap remains our most preferred company in IT. The company's earnings and margins are continuously rising. So we like this stock. "Kotak Institutional Equities recently said that considering the rapid growth of L & T Infotech, it should get higher valuation. The company has a large number of clients He has good potential in the digital segment. The brokerage house said that its growth will continue to grow fast in the coming days.
5. Division Labs
Share price: ₹ 1,478.55
Changes in Samvat 2074: 68.45%
Forward P / E: 32.12
Consensual rating: 14 bye / 1 hold / 1 cell
Consensus Target Price: ₹ 1,555.50
Division Labs is quite strong in the Contract Research and Manufacturing Services Segment. This gives the stock a touch. However, HDFC Securities had recently stated in a report that it is trading at 30 times the estimated EPS of FY2019, which is 20% more than its historical valuation. The brokerage house had recently downgraded the stock and had categorized its rating. HDFC Securities has set a target price of Rs 1,345 for division labs. Motilal Oswal also kept a neutral rating on the stock in a note in October. He has set a target of Rs 1,390 for this.
6. Biocon
Share price: ₹ 629.3
Changes in Samvat 2074: 64.73%
Forward P / E: 57.07
Consensus rating: 12 by / 2 hold / 6 cells
Consensus Target Price: ₹ 650.90
In the past some time, the interest of investors has increased in the company due to the increase in the biologics segment. Motilal Oswal says that later biological business can be strong performance. At the same time, the performance of the company's approved biosimillers in regulators and emerging markets will also be excellent. However, analysts are apprehensive of high valuation of Biocon. Motilal Oswal has given it a neutral rating. He says that the share price of Biocon is not very fast. At the same time, Centrum Broking wrote in a recent report that recently the shares of Biocon have gained a lot, making it expensive. The brokerage firm advised to switch from Aurobindo Pharma or Pfizer. He gave biocon cell rating with target price of 480 rupees.
7. TCS
Share price: ₹ 1,931.95
Changes in Samvat 2074: 49.4%
Forward P / E: 22.90
Consensual rating: 24 bye / 17 hold / 9 cells
Consensus Target Price: ₹ 2,134.89
Due to the weakness in the rupee and the defensive sector, including IT, TCS has done outperform due to the financial condition. Sharekhan, a proprietary brokerage firm owned by BNP Paribas, has given a buy rating to TCS with target price of 2,400 rupees. He said, 'We believe that compared to other big IT companies, TCS's shares will continue to meet higher valuations. The company is strong enough in the digital segment. Its organic growth is the best in big IT companies. Its digital business is also getting better.
8. Infosys
Share price: ₹ 666.80
Changes in Samvat 2074: 45.4%
Forward P / E: 22.9
Consensual rating: 24 bye / 17 hold / 9 cells
Consensus Target Price: 790.14
In addition to the Future Sentiment related to BFSI Vertical, there is a positive segmentation about the stock with faster growth. Brokerage firm Prabhudas Liladhar has written in a note, "Infosys is trading at 22% less valuation than TCS. We believe that the valuation of Infosys is attractive because its business is also improving. We believe that its valuation gap may be lower than TCS. "Brokerage House has given a buy rating of Rs 790 with Target Price of Infosys at Rs 790.
9. United Breweries
Share price: ₹ 1,252.25
Changes in Samvat 2074: 48.65%
Forward P / E: 64.97
Consensual rating: 5 bye / 1 hold / 3 cell
Consensus Target Price: ₹ 1,317.75
Growth in beer volume and profitability after the highway ban has improved significantly in United Breweries growth and profitability. Brokerage house MK Global said, 'We expect the company to profit margins.' United Breweries is trying to reduce costs. Recovery is occurring in its high margin market and the volume of volume increases, operating leverage is also increasing. There is also a steady increase in its market share. We believe that United Breweries will benefit greatly due to low competition in the beer market. "MK Global has estimated 28 percent CAGR increase in the company profits between 2019 and 2021. He says that in the meanwhile, the company's Return on Capital Employee will also improve. In this sense, the price at which it is trading is appealing.
10. GlaxoSmithKline Consumer Healthcare
Share price: ₹ 7,102.45
Changes in Samvat 2074: 43.9%
Forward P / E: 34.24
Consensual rating: 18 bye / 6 hold / 1 cell
Consensus target price: ₹ 7,914.06
Analysts say that GSK Consumer Performance has improved significantly. Management is focusing on new variants and channels, whose company is benefiting. Edelweiss Securities has raised the target price of the stock from Rs 6,604 to Rs 7,297, but has maintained its hold rating on it. Prabhudas Leeladhar also gave it a hold rating.
No comments:
Post a Comment